The NET Research Foundation provided the initial seed funding to UPenn to develop the CDH17 CART that was in-licensed by CHM.
Wouldn’t it be great if the same CDH17 CART resulted in practise changing therapy for NET cancer sufferers (including the deadly pancreatic NET that Steve Jobs died from) around the world?!?
Ann: EMORY JOINS CHM CDH17 PHASE 1/2 CLINICAL TRIAL, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(25.0%) |
Mkt cap ! $6.045M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $22.28K | 6.311M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 78 | 84735861 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 86304338 | 23 |
View Market Depth
| Last trade - 14.27pm 25/07/2025 (20 minute delay) ? |
| CHM (ASX) Chart |